Welcome to our dedicated page for 23Andme Holding Co news (Ticker: ME), a resource for investors and traders seeking the latest updates and insights on 23Andme Holding Co stock.
News for 23andMe Holding Co. (Nasdaq: ME), now renamed Chrome Holding Co. in SEC filings, centers on its evolution as a genetics-led consumer healthcare, biotechnology, and research company and on significant corporate restructuring events. Press releases describe 23andMe as a human genetics company with a mission to help people access, understand, and benefit from the human genome, and as a genetics-led consumer healthcare and research or biopharmaceutical company empowering a healthier future.
Visitors to this news feed can review updates on Chapter 11 proceedings, including the company’s voluntary filing in the U.S. Bankruptcy Court for the Eastern District of Missouri, court approvals of first-day motions, and the launch of a court-supervised sale process. Releases detail the company’s efforts to obtain debtor-in-possession financing, sell substantially all of its assets, and address operational, financial, and legal challenges, as well as subsequent SEC reports on the approved and completed sale of assets to 23andMe Research Institute.
The news stream also covers strategic and operational developments such as the exploration of strategic alternatives, workforce reductions, discontinuation of the Therapeutics operating segment, and restructuring initiatives aimed at cost reductions. Financial results announcements provide context on revenue trends, changes in operating expenses, and management’s previously stated concerns about liquidity and ability to continue as a going concern before the Chapter 11 filing.
In addition, 23andMe’s news highlights product and research updates, including new genetic reports for 23andMe+ Premium members on topics such as osteoporosis and homocysteine (MTHFR-related) levels, the launch of Discover23 for biopharma collaborators, and collaborations with partners like Mirador Therapeutics. Telehealth and preventive health initiatives, such as GLP-1 weight loss offerings on the Lemonaid Health platform and a comprehensive longevity service, also appear in company communications.
For investors and observers following ME-related developments, this page aggregates company-issued news on genetics products, research collaborations, telehealth services, financial performance, governance changes, and the ongoing Chapter 11 restructuring and asset sale process.
23andMe Holding Co. (Nasdaq: ME) reported a 23% increase in revenue for Q1 FY2022, totaling $59 million, compared to the prior year. The company's cash balance reached $770 million following a merger with VG Acquisition Corp. Despite revenue growth, net loss widened to $42 million, influenced by escalating operating expenses due to heightened R&D and marketing efforts. The company's full-year revenue guidance is projected at $250 to $260 million with anticipated net losses of $210 to $225 million. 23andMe continues to expand its therapeutics portfolio while enhancing its customer database to 11.6 million genotyped customers.
23andMe Holding Co. (Nasdaq: ME) announced that it will report its fiscal year 2022 first-quarter financial results on August 13, 2021, before market opens. A conference call will be held at 11:00 a.m. ET to discuss these results and business progress. The webcast will be available for later replay.
23andMe is recognized for its consumer genetics services and has FDA authorizations for genetic health risk reports. The company has a strong research platform, with over 180 publications pertaining to various diseases and conditions.
23andMe Holding Co. (Nasdaq: ME) announced the appointment of Dr. Valerie Montgomery Rice and Peter Taylor to its board of directors, following its recent business combination with VG Acquisition Corp. Dr. Montgomery Rice is the president of Morehouse School of Medicine, emphasizing diversity in healthcare. Peter Taylor leads initiatives focusing on educational outcomes and has extensive experience in finance. Together, they aim to enhance 23andMe's efforts in personalized medicine and improve healthcare through human genetics, positioning the company for growth.
23andMe Holding Co. has completed its merger with VG Acquisition Corp., with shares commencing trading on Nasdaq under ticker ME from June 17, 2021. The business combination was approved by shareholders on June 10, 2021, raising approximately $592 million to enhance 23andMe's consumer health and therapeutics efforts. CEO Anne Wojcicki emphasized the aim to expand personalized healthcare access. Additional board members include Evan Lovell and Peter Taylor, while Sir Richard Branson supports the company’s growth vision.
VG Acquisition Corp. (NYSE: VGAC) announced that its shareholders approved the merger with 23andMe, Inc. at a Special Meeting held on June 10, 2021. Over 87% of votes supported the merger, which is set to finalize on June 16, 2021, pending customary closing conditions. Following the merger, VGAC will be renamed to 23andMe Holding Co., with new shares trading on Nasdaq under the symbol 'ME' starting June 17, 2021. 23andMe is recognized for its consumer genetics services and the world's largest crowdsourced genetic research platform.
23andMe, Inc. has entered a merger agreement with VG Acquisition Corp. (NYSE: VGAC), aimed at creating a publicly traded entity under the ticker 'ME'. This transaction, valued at approximately $3.5 billion, is expected to close in Q2 2021. The merger will provide 23andMe with up to $984 million in cash to fuel growth initiatives. Sir Richard Branson and Anne Wojcicki will invest $25 million each in the deal. With over 80% of its customers participating in genetic research, 23andMe is positioned to advance personalized healthcare through its extensive genetic database.